Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Acute macular neuroretinopathy after blunt ocular trauma: A rare association.

Mishra S, Goel S, Nangia P, Senger D, Shah AV, Saurabh K, Roy R.

Indian J Ophthalmol. 2019 Apr;67(4):566-568. doi: 10.4103/ijo.IJO_1251_18.

2.

Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma.

Hoffman M, Gillmor AH, Kunz DJ, Johnston MJ, Nikolic A, Narta K, Zarrei M, King J, Ellestad K, Dang NH, Cavalli FMG, Kushida MM, Coutinho FJ, Zhu Y, Luu B, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Pugh TJ, Dirks PB, Strother D, Lafay-Cousin L, Resnick AC, Scherer S, Senger DL, Simons BD, Chan JA, Morrissy AS, Gallo M.

Cancer Res. 2019 May 1;79(9):2111-2123. doi: 10.1158/0008-5472.CAN-18-3441. Epub 2019 Mar 15.

PMID:
30877103
3.

Multimodal imaging characteristics of acute macular neuroretinopathy.

Saurabh K, Roy R, Shah D, Goel S, Mishra S, Senger D.

Indian J Ophthalmol. 2019 Mar;67(3):403-404. doi: 10.4103/ijo.IJO_969_18. No abstract available.

4.

No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.

Huhn K, Senger D, Utz KS, Schmidt M, Fröhlich K, Waschbisch A, Seifert F, Dörfler A, Lee DH, Linker RA.

Mult Scler Relat Disord. 2019 Jan;27:133-138. doi: 10.1016/j.msard.2018.10.020. Epub 2018 Oct 23.

PMID:
30384198
5.

A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth.

Goh ETH, Lin Z, Ahn BY, Lopes-Rodrigues V, Dang NH, Salim S, Berger B, Dymock B, Senger DL, Ibáñez CF.

Cell Chem Biol. 2018 Dec 20;25(12):1485-1494.e5. doi: 10.1016/j.chembiol.2018.09.007. Epub 2018 Oct 4.

PMID:
30293939
6.

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA, Pedersen H, Chan JA, Shen Y, Marra M, Kaplan DR, Mason W, Goodman LD, Ezhilarasan R, Kaufmann AB, Cabral M, Robbins SM, Senger DL, Cahill DP, Sulman EP, Cairncross JG, Blough MD.

PLoS One. 2018 Aug 28;13(8):e0202860. doi: 10.1371/journal.pone.0202860. eCollection 2018.

7.

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2018 Jul 18;9:16231. doi: 10.1038/ncomms16231.

8.

Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury.

Lau A, Chung H, Komada T, Platnich JM, Sandall CF, Choudhury SR, Chun J, Naumenko V, Surewaard BG, Nelson MC, Ulke-Lemée A, Beck PL, Benediktsson H, Jevnikar AM, Snelgrove SL, Hickey MJ, Senger DL, James MT, Macdonald JA, Kubes P, Jenne CN, Muruve DA.

J Clin Invest. 2018 Jul 2;128(7):2894-2913. doi: 10.1172/JCI96640. Epub 2018 Jun 4.

9.

[Critical illness myopathy and polyneuropathy].

Senger D, Erbguth F.

Med Klin Intensivmed Notfmed. 2017 Oct;112(7):589-596. doi: 10.1007/s00063-017-0339-0. Epub 2017 Sep 5. Review. German.

PMID:
28875277
10.

Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells.

Sarkar S, Mirzaei R, Zemp FJ, Wei W, Senger DL, Robbins SM, Yong VW.

Cancer Res. 2017 Jun 15;77(12):3231-3243. doi: 10.1158/0008-5472.CAN-16-2171. Epub 2017 Apr 17.

11.

The Role of Neurotrophin Signaling in Gliomagenesis: A Focus on the p75 Neurotrophin Receptor (p75NTR/CD271).

Alshehri MM, Robbins SM, Senger DL.

Vitam Horm. 2017;104:367-404. doi: 10.1016/bs.vh.2016.11.001. Epub 2017 Jan 4. Review.

PMID:
28215302
12.

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2017 Feb 15;8. doi: 10.1038/ncomms14278. Erratum in: Nat Commun. 2018 Jul 18;9:16231.

13.

Diabetic Wound Healing and Activation of Nrf2 by Herbal Medicine.

Senger DR, Cao S.

J Nat Sci. 2016;2(11). pii: e247.

15.

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells.

Corredor JC, Redding N, Bloté K, Robbins SM, Senger DL, Bell JC, Beaudry P.

Mol Ther Oncolytics. 2016 Mar 16;3:16005. doi: 10.1038/mto.2016.5. eCollection 2016.

16.

Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.

Grinshtein N, Rioseco CC, Marcellus R, Uehling D, Aman A, Lun X, Muto O, Podmore L, Lever J, Shen Y, Blough MD, Cairncross GJ, Robbins SM, Jones SJ, Marra MA, Al-Awar R, Senger DL, Kaplan DR.

Oncotarget. 2016 Sep 13;7(37):59360-59376. doi: 10.18632/oncotarget.10661.

17.

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL.

Clin Cancer Res. 2016 Aug 1;22(15):3860-75. doi: 10.1158/1078-0432.CCR-15-1798. Epub 2016 Mar 22.

18.

Activation of the Nrf2 Cell Defense Pathway by Ancient Foods: Disease Prevention by Important Molecules and Microbes Lost from the Modern Western Diet.

Senger DR, Li D, Jaminet SC, Cao S.

PLoS One. 2016 Feb 17;11(2):e0148042. doi: 10.1371/journal.pone.0148042. eCollection 2016.

19.

Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia.

Sabe AA, Potz BA, Elmadhun NY, Liu Y, Feng J, Abid MR, Abbott JD, Senger DR, Sellke FW.

J Thorac Cardiovasc Surg. 2016 Jan;151(1):245-52. doi: 10.1016/j.jtcvs.2015.08.101. Epub 2015 Sep 3.

20.

Chakyunglupulins A and B, two novel 4,8,8-trimethylcyclooct-2-enone derivatives from Barleria lupulina.

Kim KH, Clardy J, Senger D, Cao S.

Tetrahedron Lett. 2015 May 20;56(21):2732-2734.

21.

QuantitativeT2: interactive quantitative T2 MRI witnessed in mouse glioblastoma.

Ali TS, Bjarnason TA, Senger DL, Dunn JF, Joseph JT, Mitchell JR.

J Med Imaging (Bellingham). 2015 Jul;2(3):036002. doi: 10.1117/1.JMI.2.3.036002. Epub 2015 Jul 21.

22.

Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1.

Ahn BY, Saldanha-Gama RF, Rahn JJ, Hao X, Zhang J, Dang NH, Alshehri M, Robbins SM, Senger DL.

Oncogene. 2016 Mar 17;35(11):1411-22. doi: 10.1038/onc.2015.199. Epub 2015 Jun 29.

23.

ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Sarkar S, Zemp FJ, Senger D, Robbins SM, Yong VW.

Neuro Oncol. 2015 Aug;17(8):1095-105. doi: 10.1093/neuonc/nou362. Epub 2015 Feb 1.

24.

Iridoid glycosides from Barleria lupulina.

Kim KH, Park YJ, Chung KH, Yip ML, Clardy J, Senger D, Cao S.

J Nat Prod. 2015 Feb 27;78(2):320-4. doi: 10.1021/np500791a. Epub 2015 Jan 22.

PMID:
25611215
25.

Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.

26.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

27.

Angiogenesis.

Senger DR, Davis GE.

Cold Spring Harb Perspect Biol. 2011 Aug 1;3(8):a005090. doi: 10.1101/cshperspect.a005090. Review.

28.

Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis.

Hoang MV, Nagy JA, Fox JE, Senger DR.

PLoS One. 2010 Oct 25;5(10):e13612. doi: 10.1371/journal.pone.0013612.

29.

Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1.

Hoang MV, Nagy JA, Senger DR.

Blood. 2011 Feb 3;117(5):1751-60. doi: 10.1182/blood-2010-05-286831. Epub 2010 Oct 28.

30.

Cdc42-mediated inhibition of GSK-3β improves angio-architecture and lumen formation during VEGF-driven pathological angiogenesis.

Hoang MV, Nagy JA, Senger DR.

Microvasc Res. 2011 Jan;81(1):34-43. doi: 10.1016/j.mvr.2010.09.001. Epub 2010 Sep 16.

31.

Moderate GSK-3β inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy.

Hoang MV, Smith LE, Senger DR.

Angiogenesis. 2010 Sep;13(3):269-77. doi: 10.1007/s10456-010-9184-y. Epub 2010 Sep 1.

32.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA.

Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31.

33.

Calpain inhibitors reduce retinal hypoxia in ischemic retinopathy by improving neovascular architecture and functional perfusion.

Hoang MV, Smith LE, Senger DR.

Biochim Biophys Acta. 2011 Apr;1812(4):549-57. doi: 10.1016/j.bbadis.2010.08.008. Epub 2010 Sep 8.

34.

Follicular fluid-specific distribution of vascular endothelial growth factor isoforms and sFlt-1 in patients undergoing IVF and their correlation with treatment outcomes.

Savchev SI, Moragianni VA, Senger D, Penzias AS, Thornton K, Usheva A.

Reprod Sci. 2010 Nov;17(11):1036-42. doi: 10.1177/1933719110376980. Epub 2010 Aug 9.

PMID:
20697141
35.

Vascular endothelial growth factor: much more than an angiogenesis factor.

Senger DR.

Mol Biol Cell. 2010 Feb 1;21(3):377-9. doi: 10.1091/mbc.E09-07-0591.

36.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2010 Jan 15;70(2):598-608. doi: 10.1158/0008-5472.CAN-09-1510. Epub 2010 Jan 12.

37.

Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, Forsyth P, Auer RN, Dunn JF, Cairncross JG, Parney IF, Weiss S.

Stem Cells. 2009 Aug;27(8):1722-33. doi: 10.1002/stem.98.

38.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.

39.

Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.

Wang L, Rahn JJ, Lun X, Sun B, Kelly JJ, Weiss S, Robbins SM, Forsyth PA, Senger DL.

PLoS Biol. 2008 Nov 25;6(11):e289. doi: 10.1371/journal.pbio.0060289.

40.

Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996.

Roldán G, Brasher P, Vecil G, Senger D, Rewcastle B, Cairncross G, Forsyth P, Hamilton M.

Can J Neurol Sci. 2008 May;35(2):210-5.

PMID:
18574936
41.

Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression.

Davis GE, Senger DR.

Curr Opin Hematol. 2008 May;15(3):197-203. doi: 10.1097/MOH.0b013e3282fcc321. Review.

PMID:
18391785
42.

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Wu Y, Lun X, Zhou H, Wang L, Sun B, Bell JC, Barrett JW, McFadden G, Biegel JA, Senger DL, Forsyth PA.

Clin Cancer Res. 2008 Feb 15;14(4):1218-27. doi: 10.1158/1078-0432.CCR-07-1330.

43.

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2007 Sep 15;67(18):8818-27.

44.

The p75 neurotrophin receptor is a central regulator of glioma invasion.

Johnston AL, Lun X, Rahn JJ, Liacini A, Wang L, Hamilton MG, Parney IF, Hempstead BL, Robbins SM, Forsyth PA, Senger DL.

PLoS Biol. 2007 Aug;5(8):e212.

45.

Proteolytic disassembly is a critical determinant for reovirus oncolysis.

Alain T, Kim TS, Lun X, Liacini A, Schiff LA, Senger DL, Forsyth PA.

Mol Ther. 2007 Aug;15(8):1512-21. Epub 2007 May 22.

46.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.

J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57.

PMID:
17077357
47.

Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity.

Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF.

J Exp Med. 2006 Mar 20;203(3):719-29. Epub 2006 Mar 6.

48.

Transforming the bitter to better after the storm.

Senger D, Carpenter B.

Okla Nurse. 2005 Dec-2006 Feb;50(4):14-5. No abstract available.

PMID:
16372465
49.

VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype.

Nagy JA, Senger DR.

Exp Cell Res. 2006 Mar 10;312(5):538-48. Epub 2005 Nov 28. Review.

PMID:
16310771
50.

Supplemental Content

Loading ...
Support Center